222978-02-1

Basic information

• Product Name: 2-FLUORO-4-(HYDROXYMETHYL)BENZONITRILE
• Synonyms: 2-FLUORO-4-(HYDROXYMETHYL)BENZONITRILE;4-Cyano-3-fluorobenzyl alcohol;Benzonitrile, 2-fluoro-4-(hydroxymethyl)- (9CI)
• CAS NO: 222978-02-1
• Molecular Formula: C₈H₆FNO
• Molecular Weight: 151.14
• Product Categories: HALIDE;ALDEHYDE
• Mol File: 222978-02-1.mol

Chemical Properties

• Melting Point: 66-68
• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 2-FLUORO-4-(HYDROXYMETHYL)BENZONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-FLUORO-4-(HYDROXYMETHYL)BENZONITRILE(222978-02-1)
• EPA Substance Registry System: 2-FLUORO-4-(HYDROXYMETHYL)BENZONITRILE(222978-02-1)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 222978-02-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-FLUORO-4-(HYDROXYMETHYL)BENZONITRILE is used as a building block for the synthesis of bioactive molecules, contributing to the development of new pharmaceuticals. Its unique structure allows for the creation of diverse chemical entities with potential therapeutic applications.
Used in Agrochemical Production:
In the agrochemical sector, 2-FLUORO-4-(HYDROXYMETHYL)BENZONITRILE is used as a precursor in the synthesis of various agrochemicals, aiding in the development of effective products for agricultural use.
Used in Research and Development:
2-FLUORO-4-(HYDROXYMETHYL)BENZONITRILE is utilized as a precursor in research and development, enabling the creation of new chemical entities for pharmaceutical use. Its unique properties make it a valuable tool in the discovery and synthesis of novel compounds with potential therapeutic effects.

Upstream product

• 557-21-1 dicyanozinc 
• 222978-01-0 4-bromo-3-fluorobenzyl alcohol 
• 101048-76-4 4-cyano-3-fluorobenzaldehyde 
• 452-74-4 4-bromo-3-fluorotoluene 
• 153556-42-4 4-bromo-3-fluorobenzoic acid 
• 177787-22-3 4-cyano-3-fluoro-benzoyl chloride 
• 176508-81-9 4-cyano-3-fluorobenzoic acid 
• 952183-53-8 ethyl 4-cyano-3-fluorobenzoate 
• 77-92-9 citric acid 
• 268734-34-5 2-fluoro-4-(methoxycarbonyl)benzonitrile 
• 433939-83-4 4-ethenyl-2-fluorobenzonitrile 
• 440105-58-8 α,α-dibromo-4-cyano-3-fluorotoluene 

Downstream Products

• 440105-71-5 (S)-{1-[7-[(tert-butyldiphenylsilyl)oxy]naphthalen-1-yl]-2-oxopyrrolidin-3-yl}-{2-[3-(4-cyano-3-fluorobenzyl)-3H-imidazol-4-yl]ethyl}carbamic acid tert-butyl ester 
• 222978-26-9 2-Fluoro-4-[hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-benzonitrile 
• 222978-28-1 2-fluoro-4-(1-methyl-1H-imidazole-5-carbonyl)benzonitrile 
• 275807-76-6 2-fluoro-4-[amino-(1-methyl-1H-imidazol-5-yl)methyl]benzonitrile 
• 222978-25-8 acetic acid (4-cyano-3-fluorophenyl)(3-methyl-3H-imidazol-4-yl)methyl ester 
• 403825-23-0 1-(S)-N-[1-(4-cyano-3-fluorophenyl)-1-(3-methyl-3H-imidazol-4-yl)ethyl]-2-methyl-[S(R)]-propanesulfinamide 
• 275807-74-4 2-fluoro-4-(1-trityl-1H-imidazol-4-ylmethyl)benzonitrile 
• 275806-03-6 2-[3-(3-ethyl-azepan-3-yl)-phenoxy]-4-imidazol-1-ylmethyl-benzonitrile 
• 222978-23-6 2-Fluoro-4-[hydroxy-(1-trityl-1H-imidazol-4-yl)-methyl]-benzonitrile 
• 222978-24-7 acetic acid (4-cyano-3-fluorophenyl)(1-trityl-1H-imidazol-4-yl)methyl ester 

Relevant articles and documents

Mechanistic Studies into the Oxidative Addition of Co(I) Complexes: Combining Electroanalytical Techniques with Parameterization

The oxidative addition of organic electrophiles into electrochemically generated Co(I) complexes has been widely utilized as a strategy to produce carbon-centered radicals when cobalt is ligated by a polydentate ligand. Changing to a bidentate ligand prov

Optimization of Substrate-Analogue Furin Inhibitors

The proprotein convertase furin is a potential target for drug design, especially for the inhibition of furin-dependent virus replication. All effective synthetic furin inhibitors identified thus far are multibasic compounds; the highest potency was found for our previously developed inhibitor 4-(guanidinomethyl)phenylacetyl-Arg-Tle-Arg-4-amidinobenzylamide (MI-1148). An initial study in mice revealed a narrow therapeutic range for this tetrabasic compound, while significantly reduced toxicity was observed for some tribasic analogues. This suggests that the toxicity depends at least to some extent on the overall multibasic character of this inhibitor. Therefore, in a first approach, the C-terminal benzamidine of MI-1148 was replaced by less basic P1 residues. Despite decreased potency, a few compounds still inhibit furin in the low nanomolar range, but display negligible efficacy in cells. In a second approach, the P2 arginine was replaced by lysine; compared to MI-1148, this furin inhibitor has slightly decreased potency, but exhibits similar antiviral activity against West Nile and Dengue virus in cell culture and decreased toxicity in mice. These results provide a promising starting point for the development of efficacious and well-tolerated furin inhibitors.

3-ARYL AND HETEROARYL SUBSTITUTED 5-TRIFLUOROMETHYL OXADIAZOLES AS HISTONE DEACETYLASE 6 (HDAC6) INHIBITORS

The present invention is directed to substituted 5-trifluoromethyl oxadiazole compounds of generic formula (I) or a pharmaceutically acceptable salt thereof. In particular, the invention is directed to a class of aryl and heteroaryl substituted 5-trifluoromethyl oxadiazole compounds of formula I which may be useful as HDAC6 inhibitors for treating cellular proliferative diseases, including cancer, neurodegenerative diseases, such as schizophrenia and stroke, as well as other diseases.

Benzene, Pyridine, and Pyridazine Derivatives

Disclosed are compounds and pharmaceutically acceptable salts of Formula I wherein A, Q1, Q2, Q3, R31, and R41 are as defined herein. Compounds of Formula I are useful in the treatment of diseases and

Mandelic acid derivatives and their use as throbin inhibitors

There is provided a compound of formula I wherein Ra, R1, R2, Y and R3 have meanings given in the description and pharmaceutically acceptable derivatives (including prodrugs) thereof, which compounds and derivatives are useful as, or are useful as prodrugs of, competitive inhibitors of trypsin-like proteases, such as thrombin, and thus, in particular, in the treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulants.

PHARMACEUTICAL COMBINATION

There is provided a combination product comprising: (1) a compound of claim 1 in WO 02/44145 or a compound of claim 20 in WO 02/44145 (or derivative thereof)or a pharmaceutically-acceptable derivative thereof; and (1) a compound as defined in claim 1 of WO 01/28992 or (2) a compound of Claim 34 of WO 01/28992 or (3) Compound A or B or C or D (or pharmaceutically-acceptable salts thereof) for use in treating arrhythmia or a coagulation controlled complication thereof.

INHIBITORS OF PRENYL-PROTEIN TRANSFERASE

The present invention is directed to peptidomimetic piperazine-containing macrocyclic compounds which inhibit prenyl-protein transferase and the prenylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting prenyl-protein transferase and the prenylation of the oncogene protein Ras

Farnesyltransferase inhibitors

Substituted imidazoles and thiazoles having the formula are useful for inhibiting farnesyltransferase. Also disclosed are farnesyltransferase-inhibiting compositions and methods of inhibiting farnesyltransferase in a patient.

Method of treating cancer

The present invention relates to methods of treating cancer using a combination of a compound which is a PSA conjugate and a compound which is a inhibitor of prenyl-protein transferase, which methods comprise administering to said mammal, either sequentially in any order or simultaneously, amounts of at least two therapeutic agents selected from a group consisting of a compound which is a PSA conjugate and a compound which is a inhibitor of prenyl-protein transferase. The invention also relates to methods of preparing such compositions.

Dual protein farnesyltransferase-geranylgeranyltransferase-I inhibitors as potential cancer chemotherapeutic agents

A series of novel diaryl ether lactams have been identified as very potent dual inhibitors of protein farnesyltransferase (FTase) and protein geranylgeranyltransferase I (GGTase-I), enzymes involved in the prenylation of Ras. The structure of the complex formed between one of these compounds and FTase has been determined by X-ray crystallography. These compounds are the first reported to inhibit the prenylation of the important oncogene Ki-Ras4B in vivo. Unfortunately, doses sufficient to achieve this endpoint were rapidly lethal.